Stock Track | METIS TECHBIO-P Soars 5.82% on Strategic AI Drug Development Alliance with Deerfield Management

Stock Track
06/01

METIS TECHBIO-P's stock price surged 5.82% intraday on Monday, driven by positive market reaction to a significant corporate development.

The sharp increase follows the company's announcement of a strategic alliance with the premier global health investment and innovation platform, Deerfield Management. The partnership is aimed at co-developing a new generation of in vivo protein therapeutics and immunotherapies, while jointly advancing the global commercialization of collaborative pipeline products.

Under the agreement, Deerfield will engage in in-depth collaboration on the global clinical development and commercial expansion initiatives related to METIS TECHBIO-P's proprietary AI-powered nano-delivery platform, NanoForge, and its core pipeline projects. This includes a leading T-cell engager project discovered by the company's in-house AiProtein platform.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10